Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dr. Reddy's, Gilead Enter Remdesivir Licensing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dr. Reddy’s, Gilead Enter Remdesivir Licensing Agreement

Dr. Reddy’s gains right to register, manufacture and sell Gilead’s investigational Remdesivir, a potential treatment for Covid-19, in 127 countries.

By: Contract Pharma

Contract Pharma Staff

Dr. Reddy’s Laboratories Ltd. has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. granting Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of the drug. Dr. Reddy’s will be responsible for manufacturing scale up and obtaining regulatory approval for marketing of the drug in respective countries.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. FDA to treat Covid-19.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics